title: [Treating metastatic melanoma: Risk management].
authors.affiliation: Université Paris-Diderot, Sorbonne-Paris-Cité, APHP services de dermatologie et CIC, hôpital Saint-Louis-Paris, INSERM U976, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: celeste.lebbe@aphp.fr.
authors.forename: C
authors.initials: C
authors.lastname: Lebbe
authors.affiliation: Département de médecine, service de dermatologie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors.forename: C
authors.initials: C
authors.lastname: Robert
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D009362:Neoplasm Metastasis; D000077594:Nivolumab; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000077594:Nivolumab; C582435:pembrolizumab